Skip to main content

Bio-Rad to Report First-Quarter 2021 Financial Results, Thursday, April 29, 2021

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2021 on Thursday, April 29, 2021, following the close of the market. The company will discuss these results in a conference call scheduled for 3 PM Pacific Time (6 PM Eastern Time) that day.

To listen, call 855-779-9068 within the U.S. or 631-485-4862 outside the U.S., passcode: 4692298. You may also listen to the conference call live via a webcast that is available on the “Investor Relations” section of our website under “Quarterly Results” at bio-rad.com. The webcast will be available for up to a year.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with approximately 7,800 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020. Please visit bio-rad.com for further information.

Contacts:

Investor Contact:
Bio-Rad Laboratories, Inc.
Ilan Daskal, Executive Vice President
& Chief Financial Officer
510-724-7000
ir@bio-rad.com

Media Contact:
Bio-Rad Laboratories, Inc.
Tina Cuccia, Manager, Corporate Communications
510-741-6063
tina_cuccia@bio-rad.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.